{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-005030","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.942433+00:00","generated_at":"2026-06-19T22:57:02.547164+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Roivant Sciences prices upsized public offering of 30.7M common shares at $7.50, raising ~$230M gross","bullets":["Offering of 30,666,665 shares priced at $7.50 per share; gross proceeds ~$230M before expenses.","Upsized from initial 26,666,666 shares; underwriters' 30-day option exercised in full.","Bookrunners: Goldman Sachs, SVB Securities, Cowen, Cantor Fitzgerald.","Shares sold by Roivant; offering closed February 7, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-005030","json":"https://secwatch.observer/filing/0001140361-23-005030.json","markdown":"https://secwatch.observer/filing/0001140361-23-005030.md","text":"https://secwatch.observer/filing/0001140361-23-005030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123005030/0001140361-23-005030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123005030/ny20006513x5_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T22:57:02.547164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e5e5f2748083052d6881957f93e47fcd4a8518a","claim":"Roivant Sciences Ltd. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co. valued at approximately $230 million (effective 2023-02-02).","evidence_excerpt":"On February 2, 2023, Roivant Sciences Ltd. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co. (the “Representatives”), as the representatives of the underwriters named therein, relating to the issuance and sale in an underwritten offering (the “Offering”) of 30,666,665 of the Company’s common shares","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123005030/0001140361-23-005030-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co."},{"label":"Value","value":"approximately $230 million"},{"label":"Effective","value":"2023-02-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}